Today: 28 January 2026
Subscribe
Browse Category

NASDAQ:SMMT News 12 January 2026 - 14 January 2026

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

London, Jan 14, 2026, 09:03 GMT — Regular session GSK shares rose in early London trade on Wednesday after Summit Therapeutics said it struck a clinical trial collaboration with the British drugmaker to test a new cancer combination. (MarketScreener) The move lands as investors look for signposts on how much growth GSK can squeeze from its oncology pipeline before it…
14 January 2026
······
Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

New York, Jan 12, 2026, 14:55 EST — Regular session Shares of Summit Therapeutics Inc dropped roughly 11% to $17.46 Monday afternoon, after fluctuating between $20.30 and $16.51. The move came following the company’s announcement that it filed a U.S. biologics license application for its lung cancer drug ivonescimab. (Smmttx) Summit’s filing marks its first attempt to introduce ivonescimab to…
12 January 2026
····

Stock Market Today

  • Scotiabank Cuts Metro (TSE:MRU) Price Target Amid Mixed Analyst Views
    January 28, 2026, 3:38 PM EST. Scotiabank downgraded its price target for Metro (TSE:MRU) from C$110 to C$103, signaling a cautious outlook despite maintaining an 'outperform' rating. Other analysts show mixed sentiment: Royal Bank of Canada slightly raised its target to C$113 with a 'sector perform' rating, while TD Securities cut its price objective to C$113 but kept a 'buy' recommendation. Metro's stock traded lower at C$91.21, below its 50- and 200-day averages near C$98. The grocery and drugstore retailer recently reported quarterly earnings of C$1.16 per share and revenues of C$5.29 billion. Market consensus leans toward a 'hold' rating with an average target of C$106.25, reflecting cautious investor sentiment amid evolving price forecasts and steady financial performance.
Go toTop